RxDoctor Payments Data

Rebecca Samberg

Family · Casper, WYNPI 1255815965

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 110 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 42.5% of the total. 2025 is the largest year on record at $658, 4.4 times the $149 reported in 2021.

$1,980in general payments, 2019–2025

Across 110 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$841
  • Lilly USA, LLC$267
  • Amgen$233
  • Sanofi$194
  • Regeneron Healthcare Solutions, Inc.$110
  • E.r. Squibb & Sons, L.L.C.$75
  • plus $260 from 8 others

What the payments were for

  • Food & beverage$1,980100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,980 in reported general payments places this provider in the 85th percentile of 284 family providers in Wyoming.

See all family providers in Wyoming

Medicare billing

Part B allowed, 2024
$472,464
Medicare patients
1,303
Services billed
9,495

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Taltz AutoinjectorIxekizumab26$171,949
OtezlaApremilast14$67,164
Fluorouracil40$2,829
Clobetasol Propionate39$2,534
Doxycycline Monohydrate52$2,143
Metronidazole28$1,561
Triamcinolone Acetonide126$1,236
Imiquimod56$1,097
Tacrolimus12$824
Clindamycin Phosphate12$654
Ketoconazole35$534
ValacyclovirValacyclovir Hcl36$325
Clotrimazole14$170
Mupirocin13$84

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$233$67,16414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 284 family providers in Wyoming.

Other family in Casper

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →